- Home
- MBRX vs CLSD Comparison
MBRX vs CLSD Comparison
Compare MBRX & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- CLSD
- Stock Information
- Founded
- MBRX 2015
- CLSD 2011
- Country
- MBRX United States
- CLSD United States
- Employees
- MBRX N/A
- CLSD N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- CLSD Health Care
- Exchange
- MBRX Nasdaq
- CLSD Nasdaq
- Market Cap
- MBRX 23.5M
- CLSD 20.4M
- IPO Year
- MBRX 2016
- CLSD 2016
- Fundamental
- Price
- MBRX $0.44
- CLSD $3.64
- Analyst Decision
- MBRX Strong Buy
- CLSD Hold
- Analyst Count
- MBRX 4
- CLSD 4
- Target Price
- MBRX $5.00
- CLSD $65.00
- AVG Volume (30 Days)
- MBRX 5.2M
- CLSD 37.0K
- Earning Date
- MBRX 11-12-2025
- CLSD 11-07-2025
- Dividend Yield
- MBRX N/A
- CLSD N/A
- EPS Growth
- MBRX N/A
- CLSD N/A
- EPS
- MBRX N/A
- CLSD N/A
- Revenue
- MBRX N/A
- CLSD $4,166,000.00
- Revenue This Year
- MBRX N/A
- CLSD $98.20
- Revenue Next Year
- MBRX N/A
- CLSD $213.77
- P/E Ratio
- MBRX N/A
- CLSD N/A
- Revenue Growth
- MBRX N/A
- CLSD N/A
- 52 Week Low
- MBRX $0.25
- CLSD $3.32
- 52 Week High
- MBRX $3.65
- CLSD $17.10
- Technical
- Relative Strength Index (RSI)
- MBRX 42.06
- CLSD 50.42
- Support Level
- MBRX $0.46
- CLSD $3.60
- Resistance Level
- MBRX $0.51
- CLSD $4.26
- Average True Range (ATR)
- MBRX 0.05
- CLSD 0.33
- MACD
- MBRX -0.00
- CLSD -0.06
- Stochastic Oscillator
- MBRX 4.81
- CLSD 25.65
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.